Previous studies have shown that a-adrenergic activation reduces myocardial damages caused by ischemia/reperfusion. However, the molecular mechanisms of how a-adrenergic activation protects the myocardium are not completely understood. The objective of this study was to test the hypothesis that a-adrenergic activation protects the myocardium by, at least in part, inhibiting apoptosis in cardiomyocytes. The current data has shown that apoptosis in neonatal rat cardiomyocytes, induced by 24 h treatment with hypoxia (95% N 2 and 5% CO 2 ) and serum deprivation, was inhibited by co-treatment with phenylephrine. Pre-treatment with phenylephrine for 24 h also protected cardiomyocytes against subsequent 24 h treatment with hypoxia and serum deprivation. Exposure of cardiomyocytes to phenylephrine for up to 9 days under normoxic conditions did not cause apoptosis. The phenylephrinemediated cytoprotection was blocked by an a-adrenergic antagonist, phentolamine. b-adrenergic activation with isoproterenol did not protect cardiomyocytes against hypoxia and serum deprivation-induced apoptosis. Under hypoxic conditions,phenylephrinepreventedthedown-regulationofBcl-2and Bcl-X mRNA/protein and induced hypertrophic growth. Phenylephrine-mediated protection was abrogated by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin and was mimicked by the caspase-9 peptidic inhibitor LEHD-fmk. These results suggest that a-adrenergic activation protects cardiomyocytes against hypoxia and serum deprivation-induced apoptosis through regulating the expression of mitochondrion-associated apoptosis regulatory genes, preventing activation of mitochondrial damage-induced apoptosis pathway (cytochrome C-caspase-9), and activating hypertrophic growth. Cell Death and Differentiation (2000) 7, 773 ± 784.
Introduction
Sustained ischemia and reperfusion cause a series of damages to the myocardium, including death of cardiomyocytes by the mechanisms of necrosis and apoptosis. 1 ± 5 Since the majority of adult cardiomyocytes are postmitotic, death of cardiomyocytes caused by ischemia and reperfusion leads to loss of cardiac muscle mass, formation of non-contractile fibrotic tissues and thereby decreases in cardiac output. 6 ± 8 However, repeated short term treatment with ischemia and reperfusion (preconditioning) protects the myocardium from subsequent sustained ischemia and reperfusion, suggesting that preconditioning activates protective mechanisms. 9 ± 11 Further studies have shown that a-adrenergic activation is a part of preconditioning-activated protection in the myocardium. 12 ± 14 Not only is the myocardial a-adrenergic activity elevated during the ischemia and reperfusion preconditioning, but also the preconditioning-activated protection can be mimicked by administration of an a-adrenergic agonist, phenylephrine, prior to sustained ischemia and reperfusion. However, the molecular mechanisms by which a-adrenergic activation protects the myocardium from sustained ischemia and reperfusion are not completely understood.
A recent report has shown that a-adrenergic activation protects the myocardium possibly by inhibiting ischemia and reperfusion-induced apoptosis in the myocardium. 15 In that study, however, it is not completely clear whether ischemia/ reperfusion-induced apoptosis in cardiomyocytes is inhibited directly by a-adrenergic activation. On the other hand, aadrenergic activation does seem to protect isolated cardiomyocytes from cAMP-induced apoptosis. 16 It has been shown that a-adrenergic stimulation leads to activation of PI 3-kinase in both cardiac and smooth muscle cells 17, 18 and active PI 3-kinase can protect cardiomyocytes from apoptosis by activating Akt-1 kinase. 19 Active Akt-1 inhibits cytochrome C-, released from damaged mitochondria, induced activation of caspase-9 by phosphorylation.
blocked by an a-adrenergic antagonist phentolamine. bAdrenergic activation by isoproterenol, however, does not protect cardiomyocytes from hypoxia and serum deprivation. Under normoxic conditions, exposure of cardiomyocytes to phenylephrine for up to 9 days does not result in apoptosis whereas in the absence of phenylephrine and serum, cardiomyocytes start undergoing apoptosis on the second day. Phenylephrine not only inhibits the decrease in the ratios of Bcl-2:BAX and Bcl-X:BAX mRNA/protein but also induces hypertrophy under hypoxic conditions. In addition, phenylephrine-mediated protection is abrogated by co-treatment with the PI 3-kinase inhibitor wortmannin and mimicked by the caspase-9 peptidic inhibitor LEHDfmk. Thus, a-adrenergic activation may protect cardiomyocytes by maintaining mitochondrial integrity, preventing activation of the mitochondrial damage-induced apoptosis pathway (cytochrome C/caspase-9), and activating hypertrophic growth.
Results
Phenylephrine inhibits hypoxia and serum deprivation-induced apoptosis in cultured neonatal rat cardiomyocytes
To determine the effects of a-adrenergic activation on cardiomyocyte apoptosis, cultured neonatal rat cardiomyocytes were induced to undergo apoptosis by 24 h treatment with a combination of hypoxia (95% N 2 +5% CO 2 ) and serum deprivation in the presence or absence of 50 mM phenylephrine. As controls, cardiomyocytes cultured under normoxic conditions either with or without serum for 24 h were included. Apoptosis in these cardiomyocytes was assessed by a number of criteria. First, the morphology of cardiomyocytes was examined by microscopic analysis of phase images (Figure 1A ,D,G,J) and fluorescent images of cardiomyocytes from the same fields, following a dual staining with an antibody against muscle specific a-actinin ( Figure 1B ,E,H,K) and Heochst 33258 ( Figure 1C ,F,I,L). As reported previously, cardiomyocytes which were treated with hypoxia and serum deprivation for 24 h displayed a series of apoptotic morphological changes, e.g. cell shrinkage ( Figure 1D ,E, black and white arrows respectively), sarcolemma blebbing ( Figure 1D ,E, black and white arrows respectively), and nuclear condensation ( Figure 1F , white arrows). These morphologic properties characteristic of apoptosis were not observed in the majority of control cardiomyocytes cultured under normoxic conditions, either with ( Figure 1A ± C) or without serum ( Figure 1G ± I) . The above apoptotic morphologic changes, induced by hypoxia and serum deprivation, were prevented by co-treatment with 50 mM phenylephrine ( Figure 1J ± L). Cardiomyocytes cultured under hypoxia and serum deprivation for 24 h did not show spontaneous beating as the control cardiomyocytes do. However, cardiomyocytes co-treated with 50 mM phenylephrine under hypoxia and serum deprivation displayed synchronized spontaneous beating as the control cardiomyocytes (data not shown). The above results suggest that neonatal cardiomyocytes are protected by phenylephrine against hypoxia and serum deprivation-induced apoptosis.
To confirm that phenylephrine protects cardiomyocytes against hypoxia and serum deprivation-induced apoptosis, the activity of a major apoptosis executioner, caspase-3, was measured in cardiomyocytes treated with hypoxia and serum deprivation in the presence or absence of 50 mM phenylephrine. As described in the Materials and Methods section, a fluorogenic caspase-3 specific substrate, DEVD-AFC, was utilized to quantify caspase-3 activity in whole cell extracts prepared from cardiomyocytes. The endogenous caspase-3 was activated by hypoxia and serum deprivation, with its peak activity at approximately the 3 h time point (Figure 2A ). Caspase-3 activation by hypoxia and serum deprivation was inhibited by cotreatment with 50 mM phenylephrine. Suppression of hypoxia and serum deprivation-triggered caspase-3 by phenylephrine was further confirmed by the results of Western blot analysis. As shown in Figure 2B , the endogenous caspase-3 substrate. PARP (poly-adenyl ribose transferase), was degraded from a 120 kD protein to an 85 kD protein in cardiomyocytes treated with hypoxia and serum deprivation for 3 h. In both phenylephrinetreated and control cardiomyocytes, only 120 kD PARP protein was detected.
An apoptosis hallmark, triggered by caspase-3 activation, is genomic DNA fragmentation: genomic DNA degraded into the lengths of multiple mononucleosomes (n6180 bp), observed as ladders on agarose gels. Therefore, genomic DNA fragmentation was analyzed by agarose gel electrophoresis. As shown in Figure 3 , genomic DNA from cardiomyocytes cultured in the presence of both oxygen and serum was detected as a single high molecular weight band on an agarose gel, suggesting that there was no significant DNA fragmentation in these cardiomyocytes.
However, genomic DNA from cardiomyocytes cultured under normoxic conditions at the absence of serum for 24 h displayed a faint`DNA ladder' on an agarose gel, as a result of fragmentation. The signal of`DNA ladder' was much stronger with genomic DNA from cardiomyocytes treated with a combination of hypoxia and serum deprivation for 24 h. Genomic DNA fragmentation induced by hypoxia and serum deprivation was almost completely inhibited by 50 mM phenylephrine. Taken the above data together, neonatal cardiomyocytes are protected by phenylephrine against hypoxia and serum deprivationinduced apoptosis.
Phenylephrine protects cardiomyocytes through a-adrenergic receptor stimulation
To confirm that phenylephrine protects cardiomyocytes through a-, but not b-adrenergic stimulation, it was determined whether the phenylephrine-mediated cytoprotection could be inhibited by an a-adrenergic antagonist, phentolamine. Cardiomyocytes were treated with hypoxia and serum deprivation for 24 h in the presence of both phentolamine (final 5, 15, and 45 mM) and phenylephrine (final 50 mM) and apoptosis was subsequently assessed by genomic DNA fragmentation. As shown in Figure 4A , inhibition of genomic DNA fragmentation by 50 mM phenylephrine was abolished by phentolamine, indicating that phenylephrine protects cardio-myocytes through a-adrenergic stimulation. Under normoxic conditions, phentolamine had no affect on genomic DNA. Furthermore, genomic DNA fragmentation induced by 24 h treatment with hypoxia and serum deprivation was not inhibited by a b-adrenergic agonist, isoproterenol, at final concentrations of 50 and 100 mM ( Figure 4B ).
Phenylephrine alters the expression of apoptosis regulatory genes
The expression of several apoptosis controlling genes in cardiomyocytes, e.g. the members of Bcl-2 family, are regulated in response to a variety of extracellular apoptotic Figure 1 Phenylephrine inhibits hypoxia and serum deprivation-induced apoptotic morphological changes. Images of neonatal rat cardiomyocytes, cultured either under normal conditions (with both oxygen and serum, A ± C), or under hypoxia (95% N 2 +5% CO 2 ) and serum deprivation (D ± F), or under normoxia with serum deprivation (G ± I), or under hypoxia and serum deprivation in the presence of 50 mM phenylephrine (J ± L) for 24 h, were examined for apoptotic changes. Left column: phase contrast images: middle column: images of immunofluorescent staining with an anti-a-actinin antibody; right column: images of fluorescent staining with Hoechst33258. Magnification: 2006
Cell Death and Differentiation Phenylephrine protects cardiomyocytes from apoptosis H Zhu et al signals. 15,26 ± 30 To test whether phenylephrine-mediated protection involves regulation of mRNA expression of Bcl-2 family members, we measured the steady state mRNA levels of Bcl-X, Bcl-2, and BAX encoding genes by RNase protection assay. The mRNA levels of two house-keeping genes, GAPDH and L32, were measured as internal controls. As shown in Figure 5A , the steady state mRNA levels Bcl-2 and Bcl-X were down-regulated in the cardiomyocytes treated with 24 h hypoxia and serum deprivation whereas the level of BAX mRNA was not significantly changed. The hypoxia and serum deprivation-induced down-regulation of both Bcl-2 and Bcl-X mRNAs was inhibited by co-treatment with 50 mM phenylephrine. Quantification of the RNase protection results by the Storm System (Molecular Dynamics) indicated that the ratios of Bcl-X:BAX and Bcl-2:BAX were significantly reduced ( Figure 5B) by hypoxia and serum deprivation. However, the differences in these ratios between control cardiomyocytes and cardiomyocytes treated with hypoxia and serum deprivation in the presence of 50 mM phenylephrine are not statistically significant. Similar pattern of regulation of these three genes by phenylephrine at the protein level was observed by Western blot analysis ( Figure 5C ).
Phenylephrine-mediated protection is abrogated by the PI 3-kinase inhibitor wortmannin and mimicked by the caspase-9 peptidic inhibitor LEHD-fmk a-Adrenergic stimulation activates PI 3-kinase in both cardiac and smooth muscle cells. 17, 18 Active PI 3-kinase can protect cardiomyocyte against apoptosis by activating downstream Akt-1 kinase. 19 To assess whether PI 3-kinase plays any roles in phenylephrine-mediated protection, the effects of the PI 3-kinase inhibitor wortmannin were determined. Cardiomyocytes were treated with hypoxia and serum deprivation for 24 h, either with 50 mM phenylephrine or 50 mM phenylephrine plus 20 mg/ml wortmannin and apoptosis was assessed by DNA fragmentation analysis. As shown in Figure 5D , phenylephrine-mediated protection was abrogated by cotreatment with 20 mg/ml wortmannin. Since one of the
B.
A. downstream targets of PI 3-kinase is Akt-1 kinase which prevents apoptosis by inhibiting activation of caspase-9, 20 it was further determined whether inhibition of caspase-9 would protect cardiomyocytes in the absence of phenylephrine. Genomic DNA fragmentation in cardiomyocytes, induced by 24 h treatment with hypoxia and serum deprivation, was inhibited by 40 mM caspase-9 peptidic inhibitor LEHD-fmk ( Figure 5E ).
Phenylephrine induces expression of ANF mRNA and enlargement of neonatal cardiomyocytes under hypoxic conditions
Since hypertrophic growth antagonizes apoptosis in cardiomyocytes and hepatocytes, 31, 32 we investigated whether phenylephrine induces hypertrophic growth in cardiomyocytes under hypoxic conditions by examining the expression of ANF mRNA. The steady state level of ANF mRNA in cardiomyocytes treated with 24 h hypoxia and serum deprivation in the presence or absence of 50 mM phenylephrine was assessed by Northern blot analysis. As a control, RNA samples from 24 h phenylephrine-treated and nontreated cardiomyocytes cultured under normoxic conditions were included for the Northern blot analysis. The level of GAPDH mRNA was utilized as an internal control. As previously reported, the expression of ANF mRNA, one of the molecular markers for hypertrophy, was induced by phenylephrine under normoxic conditions ( Figure 6A ). Under hypoxic conditions, the expression of ANF mRNA was also induced by phenylephrine, suggesting that phenylephrine induces hypertrophic growth under hypoxic conditions. This notion was supported by further morphological examination of cardiomyocytes. As shown in Figure 1 , cardiomyocytes treated with phenylephrine displayed more organized sarcomeres than the non-treated cardiomyocytes under hypoxic conditions. Furthermore, it was assessed whether an enlargement in cardiomyocyte size under hypoxic conditions was induced by phenylephrine. Cardiomyocyte sizes were approximated by measuring the areas of cardiomyocytes stained with an anti-a-actinin antibody, using the SigmaScan Pro software (Jandel Scientific Software). For each sample, the areas of 200 cardiomyocytes were measured. As shown in Figure 6B , under hypoxic conditions, phenylephrine-treated cardiomyocytes were significantly larger than non-treated cardiomyocytes (2.4+0.4-fold, P50.05, n=5). A similar fold induction in cardiomyocyte size by phenylephrine under normoxic conditions was observed (2.6+0.6-fold, P50.05, n=5). There is no significant difference in the size of phenylephrine-treated cardiomyocytes under either hypoxic or normoxic conditions. Data from both DNA fragmentation assay ( Figure 6C ) and morphological examination (data not shown) indicates that pre-treatment with 50 mM phenylephrine under normoxic conditions for 24 h protects cardiomyocytes against subsequent 24 h insult of hypoxia and serum deprivation. Exposure of cardiomyocytes to 50 mM phenylephrine for up to 9 days (with medium change every day) does not result in apoptosis ( Figure 6D ). However, genomic 
A.
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E. Figure 5 Phenylephrine inhibits hypoxia and serum deprivation-induced down-regulation of Bcl-X and Bcl-2 mRNAs. The mRNA levels of Bcl-X, Bcl-2, and BAX genes were determined by RNase protection assay using the RiboQuant system (PharMingen). The mRNA levels of L32 and GAPDH genes were used as internal controls. Ten micrograms of total RNA from each cardiomyocyte sample were subjected to RNase protection assay using a mixture of multiple probes (Fas, FasL, Bcl-X, Bcl-2, BAX, caspase-1, caspase-2, caspase-8, L32, and GAPDH, only Bcl-X, Bcl-2, BAX, L32, and GAPDH mRNAs were repeatablly detectable). DNA fragmentation was observed on the second day of culture without phenylephrine and serum ( Figure 6E ), which is consistent with the pervious observation. 23 On the fifth day of culture without phenylephrine and serum, majority of cardiomyocytes were detached from the culture dishes (data not shown) and a stronger DNA fragmentation signal was observed ( Figure 6E ).
Discussion
Phenylephrine protects cultured cardiomyocytes against hypoxia and serum deprivation-induced apoptosis through a-but not b-adrenergic stimulation
The current data shows that phenylephrine protects cultured neonatal cardiomyocytes against hypoxia and serum deprivation-induced apoptosis through a-adrenergic stimulation. This in vitro observation, at least in part, explains the previous in vivo observation that a-adrenergic activation is involved in ischemia/reperfusion preconditioning-mediated myocardial protection against subsequent sustained ischemia/reperfusion. Since majority of cardiomyocytes become postmitotic shortly after birth, cardiomyocyte apoptosis, induced by sustained ischemia/reperfusion, could lead to loss of cardiac muscle mass and thereby deterioration of cardiac functions. Therefore, one potential mechanism by which a-adrenergic activation protects the myocardium from sustained ischemia/ reperfusion could be through inhibition of ischemia/reperfusion-induced cardiomyocyte apoptosis. A data from in vivo studies by Baghelai et al 15 suggests that a-adrenergic activation results in reduced apoptosis rate in the myocardium treated with sustained ischemia/reperfusion. Our current data shows directly the protection of isolated cardiomyocytes by a-adrenergic activation against hypoxia and serum deprivation-induced apoptosis. In addition, a-adrenergic activation may have a more general protective effect on cardiomyocytes both in vivo and in vitro. For instance, Wang and Ashraf have reported that a-adrenergic activation during Ca 2+ pre-conditioning protects the myocardium against subsequent Ca 2+ overload injury. 33 Iwai-Kanai et al 16 have shown that cAMP-induced apoptosis in cultured neonatal rat cardiomyocytes can be blocked by a-adrenergic activation.
Integrity of mitochondria and apoptosis in cardiomyocytes
In this study, we have shown that the ratios of Bcl-2:BAX and Bcl-X:BAX mRNAs/proteins are down-regulated along with the occurrence of apoptosis in neonatal cardiomyocytes by 24 h treatment with hypoxia and serum deprivation. This down-regulation, however, is effectively abrogated by the cotreatment with 50 mM phenylephrine. These results suggest that hypoxia and serum deprivation induces apoptosis in cardiomyocytes through, at least in part, by regulation of mitochondrion-associated apoptotic regulatory genes. It has been shown previously that down-regulation of Bcl-2 and Bcl-X results in leakage of mitochondrial proteins, in particular, cytochrome c into cytoplasm, which in turn activates caspase-9 with Apaf-1 and dATP. 21 Activated caspase-9 triggers an entire cascade of downstream caspase activation, including the major executioner, caspase-3. Our current data has shown that the endogenous caspase-3 is activated by hypoxia and serum deprivation. Thus, the mitochondrion/ caspase-9 pathway could play a critical role in mediating ischemia-induced apoptosis in cardiomyocytes. As a piece of supportive evidence, our data shows that phenylephrinemediated protection is abrogated by the PI 3-kinase inhibitor wortmannin. PI 3-kinase is activated by a-adrenergic stimulation 17, 18 and protects cardiomyocytes by activating Akt-1 kinase. 19 Akt-1 inhibits apoptosis, at least partially, by blocking activation of caspase-9. 20 Our data demonstrates that phenylephrine-mediated inhibition of DNA fragmentation can be mimicked by the caspase-9 peptidic inhibitor LEHDfmk. Therefore, phenylephrine may protect cardiomyocyte by the combination of maintaining the integrity of mitochondria and activating PI 3-kinase, which all lead to prevention of caspase-9 activation.
Also consistent with our observation, not only have the decreases in the ratios of Bcl-2:BAX and Bcl-X:BAX been observed in apoptotic cardiomyocytes in vivo and in vitro, 15,26 ± 30 but also the overexpression of either Bcl-2 or Bcl-X protein can protect cardiomyocytes against apoptosis. 34 ± 36 In addition, Baghelai et al 15 have also shown that a-adrenergic activation-mediated myocardial protection from sustained ischemia/reperfusion is correlated with an increase in the Bcl-X:BAX protein ratio in the myocardium. Besides Bcl-2 and Bcl-X, phenylephrine may also up-or down-regulate other apoptosis regulatory genes in cardiomyocytes in response to various insults. Therefore, our current in vitro model system provides an opportunity to identify cardiac apoptosis regulatory genes, which could potentially serve as pharmaceutical targets for intervening cardiac apoptosis.
Possible antagonistic relationship between hypertrophy and apoptosis in cultured cardiomyocytes
It has been reported that cardiomyocyte apoptosis is elevated in decompensatory hypertrophy, suggesting that hypertrophy could lead to apoptosis. 37 ± 40 However, our current data shows that a well-characterized hypertrophy stimulus, phenylephrine, not only does not induce apoptosis in cultured neonatal cardiomyocytes under in vitro normoxic conditions, but it protects these cardiomyocytes against hypoxia and serum deprivation-induced apoptosis. In addition, cardiomyocytes pre-treated with phenylephrine for 24 h are protected from subsequent 24 h treatment with hypoxia and serum deprivation. This apparent discrepancy could be explained by at least two possibilities. First, sustained hypertrophy in vivo could become decompensatory, which results in a number of detrimental changes in the ventricular muscle. For instance, regional ischemia can be evoked by the combination of thickening of ventricular wall and lack of appropriate angiogenesis during decompensatory hypertrophy, 41, 42 which can induce cardiomyocyte apoptosis. 1 ± 5,43 ± 46 In addition, decompensatory hypertrophy can also be accompanied by infiltration of macrophages and neutrophils in the ventricular muscle which secrete pro-apoptosis cytokines Cell Death and Differentiation Phenylephrine protects cardiomyocytes from apoptosis H Zhu et al such as IL-1b, TNFa, NO, and angiotensin II. 30, 47, 48 Therefore, cardiomyocyte apoptosis could be a direct result of these decompensatory hypertrophy-triggered detrimental changes, instead of hypertrophic growth itself. Consistent with this notion, elevation in cardiomyocyte apoptosis during compensatory hypertrophy, which is not accompanied by the above detrimental changes, has not been observed. There is probably not always a cause-and-effect relationship between the onset of hypertrophic program and the onset of apoptotic program in cardiomyocytes. This notion is supported by an observation that hypertrophy in neonatal cardiomyocytes is mediated by the b-isoform of p38 mitogen-activated protein kinase whereas apoptosis is mediated by the a-isoform. 49 On the other hand, cardiomyocytes, induced to develop hypertrophy in vitro, do not encounter those detrimental changes occurring during decompensatory hypertrophy in vivo since there is always sufficient oxygen and serum in the culture medium. Furthermore, cardiomyocytes begin hypertrophic program with a transient activation of several protooncogenes, such as c-jun, c-fos, c-myc, erg-1, and nur77, and subsequent activation of the ras/ERK signaling pathway. 50 ± 52 Hence, it is not difficult to envision that activation of hypertrophy could potentially antagonize apoptosis in cardiomyocytes. Tone et al 53 has shown that LIF can protect cardiomyocytes against apoptosis by activating the JAK-STAT signaling pathway, which is also involved in hypertrophic growth. Double allelic null mutations of the gp130 gene, which encodes a component of LIF receptor, lead to massive myocyte apoptosis in response to pressure overload. 54 It has been shown in both cardiomyocytes and hepatocytes, activation of hypertrophic growth antagonizes apoptosis. 31, 32 These observations suggest an antagonistic relationship between hypertrophic growth and apoptotic cell death. Despite the above examples, the antagonistic effects of hypertrophy on apoptosis may not be a universal rule since the Gq pathway can lead to hypertrophy and apoptosis depending upon the level of activation. 55 The second possibility is that in addition to activating hypertrophy, phenylephrine also regulates expression of apoptosis regulatory genes in cardiomyocytes, which are independent of hypertrophic growth. Our current results have shown that the expression of two mitochondrionassociated anti-apoptotic genes. Bcl-2 and Bcl-X, in cultured neonatal cardiomyocytes is regulated by phenylephrine under hypoxic conditions. This regulation could account for a part of phenylephrine-mediated cytoprotection. Although it is difficult to distinguish these two possibilities at present, it is likely that both possibilities contribute to the phenylephrine-mediated protection. More experiments are needed to assess the relative importance of these two possible mechanisms.
In conclusion, our current studies indicate that apoptosis is not an obligatory consequence of hypertrophy in isolated neonatal cardiomyocytes. To our best knowledge, our data, for the first time, demonstrates that hypoxia and serum deprivation-induced cardiomyocyte apoptosis in vitro can be effectively inhibited by a hypertrophy-inducing stimulus, phenylephrine. Although a-adrenergic receptor agonists may not be ideal pharmaceutical targets for intervening in apoptosis due to reasons such as vasoconstriction. It can be conceptually envisioned that phenylephrine-regulated genes may potentially serve as pharmaceutical targets.
Materials and Methods

Isolation and culturing of neonatal rat cardiomyocytes
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). The isolation and culture of neonatal rat ventricular myocytes are described previously. 56 Sprague-Dawley is the only rat strain utilized for all the experiments performed in the current studies. Ventricular myocytes were dispersed from the ventricles of 1-day-old neonatal rats by digestion with collagenase II (Worthington) and pancreatin (GIBCO BRL) at 378C. Myocytes were further purified by a discontinuous Percoil (Pharmacia Biotechnology Inc) gradient to obtain myocardial culture with 495% myocytes, as assessed by immunofluorescence staining with an antibody (EA53. Sigma) against muscle specific a-actinin. Myocytes were plated on collagen type I-coated 10-cm dish (5610 6 cells per dish) or 2-well chamber slides (0.5610 6 cells per well) (BIOCOAT Becton Dickinson) in DMEM+199 (4 : 1)+5% FBS+10% horse serum for 36 h with one change of medium. To induce apoptosis, myocytes were switched to serum-free medium and placed in a hypoxic chamber (Forma Scientific) with 95% N 2 +5% CO 2 for 24 h. The caspase-9 peptidic inhibitor, LEHD-fmk. 57 was purchased from Enzyme System Products.
Assessment of cardiomyocytes apoptosis
The morphology of myocytes was examined by phase contrast and fluorescent microscopy following immunofluorescent staining with an anti-a-actinin antibody and Hoechst33258. Myocytes in one well of 2-well chamber slides were rinsed with PBS and fixed for 15 min 258C in 2 ml of 3% paraformaldehyde in buffer A (10 mM sodium phosphate, pH 7.4, 150 mM NaCl, and 1 mM MgCl 2 ). The cells were changed into 2 ml of 50 mM NH 4 Cl in buffer A and incubated at 258C for 10 min. After they were washed twice with PBS, the cells were permeabilized with 2 ml of 0.2% Triton X-100 in buffer A at 258C for 15 min, followed by three additional washes with PBS. The slides were blocked with 1% bovine serum albumin for 10 min at 258C, incubated with an antibodies against muscle specific a-actinin (diluted 20-fold) for 60 min at 378C, rinsed, and washed four times with PBS. The cells in chamber slides were then incubated with a goat anti-mouse IgG antibody-conjugated with a CY2 fluorescent dye at 378C for 60 min. After being rinsed once and washed four times with PBS, they were stained with Hoechst33258 (0.1 mg/ml in PBS) at 258C for 10 min. Following two washes with PBS, the slides were mounted on glass coverslips with Anti-Fade and viewed by fluorescence microscopy. Images of phase, fluorescent staining with the anti-a-actinin antibody and Hoechst33258 from the same fields were recorded from a Nikon TE300 microscope by a Image-Pro Plus v4.0 program (Media Cybernetics). The areas of myocytes were measured by SigmaScan 3.0 software (Jandel Scientific Software) using the images of myocytes stained with the anti-a-actinin antibody and used as the approximation of the cell size. For each sample, the areas of 200 myocytes were measured by this method.
An ApoAlert Caspase-3 Fluorescent Assay Kit (Clontech) was utilized to measure the activity of endogenous caspase-3 activity. Myocytes cultured in a 10-cm dish were washed twice with ice-cold PBS and harvested by scrapping and centrifugation in a microfuge Cell Death and Differentiation Phenylephrine protects cardiomyocytes from apoptosis H Zhu et al (4000 r.p.m. for 10 min at 48C). Myocytes were then lysed in 100 ml Lysis Buffer for 10 min on ice and cell debris was removed by centrifugation in a microfuge (15 000 r.p.m. for 3 min at 48C). Caspase-3 reaction was carried out by incubating the mixture of 50 ml cell lysate. 50 ml 26Reaction Buffer, and 5 ml substrate (DEVD-AFC, 50 mM final) at 378C for 2 h. The activity of caspase-3 was quantified by measuring the fluorescence (400-nm excitation, 505-nm emission) of each reaction using a VersaFluor fluorometer (BioRad).
Western blot analysis was carried out, using an WesternBreeze kit (Novex), according to the vendor's protocol, to detect the endogenous PARP protein. Twenty micrograms of total protein from each sample were separated by SDS ± PAGE, transferred to nitrocellulose membrane (BioRad), and probed with an anti-PARP (Stratagene), or Bcl-2 (Santa Cruz Biotechnology), or Bcl-X S/L (Santa Cruz Biotechnology), or Bax (Santa Cruz Biotechnology) antibody. Antibody binding was detected by an goat anti-mouse or rabbit IgG antibody and chemiluminescence.
To detect DNA fragmentation by gel electrophoresis, genomic DNA was isolated from myocytes using a DNA Isolation Kit (Puregene) and resolved on a 1.5% agarose gel. Myocytes in one 10-cm dish were rinsed with 10 ml PBS at room temperature and lysed in 600 ml Lysis Buffer. Lysate was transferred to a clean 1.5-ml microfuge tube containing 3 ml RNaseA (20 mg/ml) and incubated at 378C for 1 h. After being cooled to room temperature, the lysate was then mixed with 200 ml of Protein Precipitation Solution and centrifuged in a microfuge at 15 000 r.p.m. for 3 min at room temperature. The supernatant was transferred to a fresh 1.5-ml microfuge tube and mixed with 600 ml 100% isopropanol. DNA was pelleted by centrifugation in a microfuge at 15 000 r.p.m. for 1 min at room temperature and washed with 1 ml 70% ethanol. After air drying for 15 min. DNA was re-hydrated in 50 ml DNA Hydration Solution over night at 48C. Five micrograms of isolated genomic DNA were resolved on a 1.5% agarose gel and viewed by ethidium bromide staining. Alternatively, 0.5 mg genomic DNA was labeled by incubating with 5 units of terminal deoxynucleotidyl transferase and 3 ml [a-
32 P]-dATP (10 mi/ml) in 30 ml 16Tailing Buffer (Stratagene) for 1 h at 378C. The unincorporated [a-
32 P]-dATP was removed by a Chrom-30 spin column (Sigma) according to manufacture's protocol. Labeled DNA was resolved on a 1.5% agarose gel, dried. and followed by autoradiography.
Northern blot analysis
Total RNA was isolated from myocytes using the TRIZOL Reagent (GIBCO BRL). After one wash with 10 ml PBS at room temperature, myocytes in a 10-cm dish were lysed in 1 ml TRIZOL Reagent and the lysate was mixed in a clean 1.5-ml microfuge tube with 0.2 ml chloroform and incubated at room temperature for 3 min. After centrifugation in a microfuge at 15 000 r.p.m. for 15 min at 48C, the RNA supernatant was mixed with 0.5 ml 100% isopropanol in a fresh 1.5-ml microfuge tube and the mixture was centrifuged in a microfuge at 15 000 r.p.m. for 10 min at 48C to pellet RNA. After one wash with 1 ml 75% ethanol. RNA pellet was resuspended in 30 ml RNase-free H 2 O. Twenty micrograms of total RNA of each sample were resolved on a 1% formaldehyde agarose gel and transferred from the agarose gel to a nylon membrane by capillary blotting and fixed by UV crosslinking. Prehybridization was carried out in an ExpressHyb Solution (Clontech) for 30 min at 688C and hybridization was carried out in fresh ExpressHyb Solution containing radiolabeled cDNA probe for 1 h at 688C. The RNA blot was washed three times in Wash Solution I (26SSC+0.05% SDS) for 10 min each at room temperature, twice in Wash Solution II (0.16SSC+0.1% SDS) for 20 min each at 508C. The blot was then exposed to Kodak X-ray film.
RNase protection assay
RNase protection assay was performed to measure the steady state levels of mRNAs for several apoptosis regulatory genes using the RiboQuant kit (PharMingen). The mRNA levels of the ribosomal protein. L32, and GAPDH were used as the internal controls. Radioactive RNA probes were synthesized in a reaction containing 1 ml RNasin (40 u/ml), 1 ml GACU pool (2.75 mM of GTP, ATP, CTP, and 61 mM UTP), 2 ml DTT (100 mM), 4 ml 56Transcription Buffer, 1 ml RPA Template Set. 10 ml [a-
32 P]-UTP (3000 Ci/mmol) and 1 ml T7 RNA polymerase (20 u/ml) for 1 h at 378C. The reaction was terminated by adding 2 ml DNase and incubating for 30 min at 378C. Phenol-chloroform extraction was carried out after the followings are added to each reaction: 26 ml 20 mM EDTA. 25 ml Tris-saturated phenol. 25 ml chloroform:isoamyl alcohol (50 : 1), and 2 ml yeast tRNA (2 mg/ml). RNA probes were then precipitated with 50 ml 4 M ammonium acetate and 250 ml 100% ethanol and resuspended in 50 ml Hybridization Buffer. Ten micrograms of total RNA resuspended in 8 ml Hybridization Buffer were mixed with 2 ml radioactive RNA probes (*5610 4 Cherenkov counts) and heated at 908C for 1 min. The mixture was cooled down gradually to 568C and incubated at 568C for 16 h. After being further cooled down gradually to 378C, RNase digestion was performed by adding 125 ml RNase Buffer and 0.3 ml RNase A/T1 and incubating at 308C for 45 min. RNase digestion was terminated by Proteinase K digestion with 19 ml Proteinase Buffer+1.5 ml Proteinase K (10 mg/ml)+30 ml tRNA (2 mg/ml) for 15 min at 378C. Phenol/chloroform extraction and ethanol precipitation were carried out as described above and the RNA pellet was resuspended in 5 ml sequencing gel loading buffer. The reaction was resolved on a precasted 8% sequencing gel (Norvex) which was then dried in a microwave oven (3 min) and exposed to Kodak X-ray film.
Statistics
Values of experimental data were expressed as mean+S.E.M. Statistical analysis was performed using the Mann-Whitney U-test. Results were considered significant if P50.05.
